US › Healthcare

Voyager Therapeutics Inc (VYGR)

US · Healthcare · Biotechnology

$1.86+8.43%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$3.2M

Revenue YoY

-39.1%

Net profit

$-24.5M

EPS

$-0.40

EPS estimate

$-0.55

Net margin

-773.2%

EPS came in at -0.40 against a street estimate of -0.55 — a beat of 27.3%.

Key statistics

Market cap

$106.0M

Forward P/E

8.4

P/B

0.75

Book value

$2.17

EPS (TTM)

$-1.81

52-week high

$5.48

52-week low

$1.68

50-day MA

$2.58

200-day MA

$3.42

Beta

1.17

Analyst view

Analysts rate Voyager Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $14.89.

Shareholding

Insiders

14.84%

Institutions

58.66%

Largest institutional holders

Fund	Stake
BlackRock Inc	8.39%
Millennium Management LLC	7.21%
Armistice Capital, LLC	5.58%
Vestal Point Capital LP	4.26%
Vanguard Capital Management, LLC	3.81%
Geode Capital Management, LLC	2.16%
Opaleye Management Inc	1.92%
State Street Corp	1.75%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Voyager Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.